|Bid||32.44 x 900|
|Ask||33.81 x 900|
|Day's Range||31.61 - 34.55|
|52 Week Range||2.14 - 52.55|
|Beta (3Y Monthly)||-0.28|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 24, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||52.80|
AQR Capital Management is a $226 billion global investment management firm launched back in 1998, by a guru in the financial world, billionaire Cliff Asness. Among other accomplishments, he became well regarded in the investing universe, thanks to his doctoral dissertation for which he closely studied the use of technical analysis to determine undervalued stocks. During […]
This month, of the total ten analysts covering Tandem Diabetes Care (TNDM), seven have given the stock a “buy” or higher rating and three have given it a “hold” rating. The mean rating for Tandem Diabetes Care stock is 2.1 with a price target of $52.8, implying an upside potential of 65% over the closing price of $32.0 on November 13.
For fiscal 2018 and 2019, Tandem Diabetes Care’s gross margins are expected at 47.13% and 51.78%, respectively, compared with 40% in fiscal 2017. The fiscal 2018 gross margins of peers DexCom (DXCM), Insulet (PODD), and Johnson & Johnson (JNJ) are expected at 64.29%, 65.59%, and 70.43%, respectively. Tandem Diabetes Care incurred selling, general, and administrative expenses of $29.51 million in the third quarter of 2018, versus $20.12 million in the third quarter of 2017.
Tandem Diabetes Care’s (TNDM) interest and other expenses fell from $2.93 million in the third quarter of 2017 to $1.40 million in the latest quarter. Tandem Diabetes Care’s net loss widened from $16.03 million in the third quarter of 2017 to $34.26 million in the latest quarter, which translated into a net loss per share of $0.62 in the third quarter of 2018. Its net loss per share was $3.09 in the third quarter of 2017. Tandem Diabetes Care stock rose significantly from $2.52 on January 5 to $51.17 on September 13, which was its high point for 2018.
Tandem Diabetes Care’s (TNDM) key focus is its t:slim X2 insulin delivery system, which is designed to display continuous glucose monitoring directly on pumps’ home screens. This is the only pump capable of remote feature updates on the US market. Tandem also sells disposable products such as cartridges and infusion sets that are used with its pumps and replaced periodically. In August 2018, Tandem began the commercialization of the t:slim X2 in key regions outside the United States.
Tandem Diabetes Care®, Inc. , a leading insulin delivery and diabetes technology company, today announced that Kim Blickenstaff, President and Chief Executive Officer and Leigh Vosseller, EVP and Chief Financial Officer, will present at the Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018 in Scottsdale, AZ at 12:20pm Eastern Time .
Tandem Diabetes Care®, Inc. , a leading insulin delivery and diabetes technology company, today announced it has been named a top workplace in San Diego by The San Diego Union-Tribune and awarded a “Future Forward” 2018 Top Workplaces honor.
Tandem Diabetes Care®, Inc. , a leading insulin delivery and diabetes technology company, today announced that management will present at the following upcoming inves
NEW YORK, NY / ACCESSWIRE / November 8, 2018 / U.S. markets advanced on Wednesday as the midterm election results went according to market expectations. The Democrats took over the House, while the Republicans ...
Kim Blickenstaff became the CEO of Tandem Diabetes Care Inc (NASDAQ:TNDM) in 2007. First, this article will compare CEO compensation with compensation at similar sized companies. Then we’ll look at Read More...
Impressive domestic sales along with the recent launch of the t:slim X2 Insulin Pump in select international markets drove Tandem Diabetes' (TNDM) revenue beat in Q3.
NEW YORK, NY / ACCESSWIRE / November 2, 2018 / U.S. markets rallied on Thursday, with the S&P 500 Index logging its first 3-day win streak in six weeks, as trade concerns between the U.S. and China continued ...
Tandem Diabetes Care®, Inc. , a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2018.
• Array BioPharma (ARRY) gained $1.16 to $16.20 Wednesday after posting quarterly results that topped Wall Street expectations. The move broke the stock out above key lateral resistance as it has emerged from a head-and-shoulders bottoming pattern. Volume of 6.5 million shares was the biggest for the drug developer since May when its stock last broke out.
Strong domestic sales along with the recent launch of the t:slim X2 Insulin Pump in selected international markets likely to drive Tandem Diabetes' (TNDM) Q3 earnings.
NEW YORK, Oct. 24, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Johnson & Johnson’s (JNJ) Diabetes Care segment generated revenues of $319.0 million in the third quarter, reflecting an ~22.2% YoY (year-over-year) decline and an 11.0% decline sequentially. Johnson & Johnson’s Diabetes Care segment reported an ~20.0% YoY operational decline in the third quarter.
Seven of the total ten analysts covering Tandem Diabetes Care (TNDM) in October 2018 have given Tandem a “buy” or higher rating, and three analysts have given Tandem a “hold” rating. The mean rating for Tandem is 2.1 with a target price of $52.5, which implies an upside potential of 36.7% over Tandem’s trading price of $38.40 on October 17.
Tandem Diabetes Care (TNDM) is expected to incur a net loss of $18.22 million in the third quarter of 2018. Its net loss was $16.03 million in the year-ago period, which translates into a net loss per share of $0.33 for the third quarter of fiscal 2018 as compared with a net loss per share of $3.09 for the third quarter of fiscal 2017. On October 12, Tandem announced that its t:slim X2 insulin pump received approval in Canada and is the only continuous glucose monitoring (or CGM) integrated insulin pump approved in the country.
Tandem Diabetes (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tandem Diabetes Care (TNDM) is expected to report its third-quarter of fiscal 2018 earnings on November 1. In this series, we’ll take a look at Tandem’s expected top line, operational, and bottom-line performance for the third quarter of 2018, analysts’ recommendations, and the performance of Tandem stock so far this year.
Tandem Diabetes Care®, Inc. , a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring integration, plans to release its third quarter 2018 results after the financial markets close on Thursday, November 1, 2018.
Tandem Diabetes Care®, Inc. (TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring (CGM) integration, today announced that it has received a Heath Canada Medical Device License for the t:slim X2™ Insulin Pump. The t:slim X2 Pump features Dexcom G5® Mobile CGM integration,1 making it the only CGM-integrated insulin pump approved in Canada for making daily diabetes treatment decisions without fingersticks.2 The Company plans to launch the t:slim X2 Insulin Pump on a province-by-province basis throughout the fourth quarter of 2018 pending the completion of pre-launch activities, including product registration with provincial health programs.